Can a 22-year-old woman with generalized anxiety disorder be treated with escitalopram (Lexapro)?

Escitalopram (Lexapro) for GAD in a 22-Year-Old Female

Yes, escitalopram is FDA-approved and appropriate for treating generalized anxiety disorder in a 22-year-old woman, but requires enhanced monitoring for suicidality during the first 1-2 months of treatment given her age falls within the high-risk young adult category.

FDA Approval and Dosing

Escitalopram is FDA-approved for GAD in adults and pediatric patients 7 years and older 1. For this 22-year-old patient:

• Start at 10 mg once daily (morning or evening, with or without food)
• May increase to maximum 20 mg daily after at least 1 week if needed based on clinical response 1
• Screen for bipolar disorder history before initiating treatment 1

Critical Safety Consideration: Suicidality Risk

The FDA black box warning specifically highlights increased risk of suicidal thoughts and behaviors in young adults (which includes your 22-year-old patient) 1. This is not theoretical:

• Begin monitoring within 1-2 weeks of starting treatment 2, 1
• Watch for agitation, irritability, unusual behavioral changes, or worsening depression 2
• The highest suicide attempt risk occurs during the first 1-2 months 2
• Schedule frequent follow-up visits during this critical window

Efficacy Evidence

Escitalopram demonstrates robust efficacy for GAD in adults:

• Pooled analysis of multiple trials showed significant improvement beginning at week 1-2 and continuing through week 8 3
• Mean HAMA score improvement: -11.3 for escitalopram vs -7.4 for placebo (p<0.001) 4
• Response rates: 58% escitalopram vs 38% placebo 4
• Long-term relapse prevention: Only 19% relapsed on escitalopram vs 56% on placebo over 24-76 weeks, with 4-fold lower relapse risk 5

Treatment Algorithm

Week 0-2:

• Start 10 mg daily
• Weekly contact (phone or in-person) to assess suicidality, agitation, behavioral changes
• Assess therapeutic response and adverse effects 2

Week 2-6:

• Continue monitoring every 1-2 weeks
• If inadequate response by week 6-8, consider increasing to 20 mg daily 2, 1

Week 8 onwards:

• If no adequate response by 6-8 weeks, modify treatment (switch agents or add therapy) 2
• If responding well, continue treatment for at least 6 months to prevent relapse 5

Common Pitfalls to Avoid

1. Underestimating young adult suicide risk: The 18-24 age group has elevated risk compared to older adults—this patient requires the same intensive monitoring as adolescents 1

2. Premature discontinuation: Abrupt cessation causes withdrawal symptoms (dizziness, nervousness, insomnia). Always taper gradually 1, 5

3. Stopping too early after remission: Relapse risk remains high; continue treatment 6+ months after achieving remission 5

4. Missing bipolar disorder: Screen for personal/family history before starting, as antidepressants can trigger mania 1

Tolerability Profile

Escitalopram is generally well-tolerated in GAD:

• Discontinuation due to adverse events: 7-9% (similar to placebo 5-8%) 5, 4
• Most common side effects are mild-moderate and include nausea, headache, insomnia 2
• Lower sexual dysfunction rates compared to paroxetine 2

Bottom Line

Prescribe escitalopram 10 mg daily with mandatory close monitoring for suicidality during the first 8 weeks, particularly the first month. The drug is effective and FDA-approved for this indication and age group, but the young adult age (22 years) places her in the highest-risk category for treatment-emergent suicidal ideation. Schedule weekly contact initially, assess response by 6-8 weeks, and plan for at least 6 months of continuation therapy if she responds 2, 1, 5.